Monte Rosa Therapeutics (GLUE) Price & Analysis

Compare

342 Followers

GLUE Stock Chart & Stats

$14.32

-$0.20(-2.99%)

At close: Jan 08 4:00 PM EST

$14.32

-$0.20(-2.99%)

Day’s Range― - ―

52-Week Range$3.50 - $14.11

Previous CloseN/A

Volume283.19K

Average Volume (3M)1.13M

Market Cap

$915.56M

Enterprise Value$259.48M

Total Cash (Recent Filing)$391.26M

Total Debt (Recent Filing)$40.17M

Price to Earnings (P/E)46.9

Beta1.32

Next Earnings

Mar 12, 2026

EPS Estimate

-0.34

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.33

Shares Outstanding65,117,760

10 Day Avg. Volume1,126,434

30 Day Avg. Volume1,128,776

Financial Highlights & Ratios

PEG Ratio0.11

Price to Book (P/B)2.30

Price to Sales (P/S)6.78

P/FCF Ratio13.50

Enterprise Value/Market Cap0.28

Enterprise Value/Revenue1.43

Enterprise Value/Gross Profit1.54

Enterprise Value/Ebitda13.27

Forecast

1Y Price Target

$18.00

Price Target Upside25.70% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)-0.22

Revenue Forecast (FY)$136.43M

Bulls Say, Bears Say

Bulls Say

Collaborations And PartnershipsMonte Rosa announced a second collaboration agreement with Novartis, which provides validation for positive Phase 1 study results and Monte Rosa's platform.

Financial PositionThe company's cash position is strong with a runway through 2028.

Pipeline DevelopmentMonte Rosa's lead asset, MRT-6160, has completed a Phase 1 study and is advancing toward multiple Phase 2 trials, supported by a partnership with Novartis.

Bears Say

Market SentimentShort interest in Monte Rosa is at 30.6% of the float.

Monte Rosa Therapeutics News

Monte Rosa Therapeutics presents preclinical data on MRT-8102

Monte Rosa Therapeutics (GLUE) announced the company will present preclinical data on the potential of MRT-8102 at the...

4d ago

GLUE

Monte Rosa Therapeutics reports Q3 revenue $12.8M, consensus $7.37M

“With three programs in clinical development and a highly productive drug discovery engine creating additional future opportunities, we...

7d ago

GLUE

Monte Rosa Therapeutics sees cash runway through 2028

Cash, cash equivalents, restricted cash, and marketable securities as of September 30, 2025, were $396.2 million, compared to...

7d ago

GLUE

Monte Rosa Therapeutics presents preclinical data at ACR on MRT-6160

Monte Rosa Therapeutics (GLUE) announced the company will present preclinical data on the potential of MRT-6160, a rationally...

20d ago

GLUE

Monte Rosa Therapeutics Reports Strong Revenue Growth

Monte Rosa Therapeutics, Inc. ( ($GLUE) ) has released its Q3 earnings. Here is a breakdown of the...

7d ago

GLUE

Monte Rosa Therapeutics: Promising Advancements and Financial Stability Drive Buy Rating

TD Cowen analyst Marc Frahm has maintained their bullish stance on GLUE stock, giving a Buy rating today....

7d ago

GLUE

Monte Rosa Therapeutics: Strategic Partnerships and Growth Potential Justify Buy Rating

LifeSci Capital analyst Oliver McCammon has maintained their bullish stance on GLUE stock, giving a Buy rating on...

7d ago

GLUE

Monte Rosa Announces Q3 Results and Novartis Collaboration

The latest announcement is out from Monte Rosa Therapeutics ( ($GLUE) ). On November 6, 2025, Monte Rosa...

7d ago

GLUE

Monte Rosa Therapeutics Advances MRT-2359 in MYC-Driven Cancer Study

Monte Rosa Therapeutics, Inc. (($GLUE)) announced an update on their ongoing clinical study. Monte Rosa Therapeutics, Inc. is...

17d ago

GLUE

Monte Rosa Therapeutics Advances with MRT-8102: A Promising Phase 1 Study

Monte Rosa Therapeutics, Inc. (($GLUE)) announced an update on their ongoing clinical study. Monte Rosa Therapeutics, Inc. is...

17d ago

GLUE

Novartis Stock (NVS) Pops as U.S. Approves Pill to Treat Stubborn Skin Flare-Ups

Swiss pharmaceutical giant Novartis ($NVS) has secured the approval of the U.S. health regulator for its new pill...

1M ago

NVS

PFE

Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!

Investors looking for all of the latest insider trades, regulatory actions, and other stock market news are in...

2M ago

Tesla CEO buys shares, China says Nvidia broke antitrust law: Morning Buzz

The major averages were mixed near noon, with traders focused on President Trump’s comments on U.S.-China trade negotiations...

2M ago

Monte Rosa’s Stock (GLUE) Skyrockets on $5.7B Deal with Novartis

Swiss giant drug producer Novartis ($NVS) has found a new destination for its recent partnership spree. On Monday,...

2M ago

NVS

ARWR

GLUE FAQ

What was Monte Rosa Therapeutics’s price range in the past 12 months?

Monte Rosa Therapeutics lowest stock price was $3.50 and its highest was $14.11 in the past 12 months.

What is Monte Rosa Therapeutics’s market cap?

Monte Rosa Therapeutics’s market cap is $915.56M.

When is Monte Rosa Therapeutics’s upcoming earnings report date?

Monte Rosa Therapeutics’s upcoming earnings report date is Mar 12, 2026 which is in 119 days.

How were Monte Rosa Therapeutics’s earnings last quarter?

Monte Rosa Therapeutics released its earnings results on Nov 06, 2025. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.348 by $0.018.

Is Monte Rosa Therapeutics overvalued?

According to Wall Street analysts Monte Rosa Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Monte Rosa Therapeutics pay dividends?

Monte Rosa Therapeutics does not currently pay dividends.

What is Monte Rosa Therapeutics’s EPS estimate?

Monte Rosa Therapeutics’s EPS estimate is -0.34.

How many shares outstanding does Monte Rosa Therapeutics have?

Monte Rosa Therapeutics has 65,117,760 shares outstanding.

What happened to Monte Rosa Therapeutics’s price movement after its last earnings report?

Monte Rosa Therapeutics reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.348. Following the earnings report the stock price went up 5.686%.

Which hedge fund is a major shareholder of Monte Rosa Therapeutics?

Currently, no hedge funds are holding shares in GLUE

Monte Rosa Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

9.28%

Trailing 12-Months

Asset Growth

45.94%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on the discovery and development of novel small molecules that harness the body's natural mechanisms to selectively degrade disease-causing proteins. The company operates within the pharmaceutical and biotechnology sectors, with a primary emphasis on advancing therapies for cancer and other serious diseases through its proprietary drug discovery platform.

Monte Rosa Therapeutics (GLUE) Earnings & Revenues

Historic Earnings Reports

GLUE Stock 12 Month Forecast

Average Price Target

$18.00

▲(25.70% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","12":"$12","21":"$21","7.5":"$7.5","16.5":"$16.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$18.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,7.5,12,16.5,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Apr<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.85,13.4,13.95,14.5,15.05,15.6,16.15,16.7,17.25,17.8,18.35,18.9,19.45,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.85,13.246153846153845,13.642307692307693,14.038461538461538,14.434615384615384,14.830769230769231,15.226923076923077,15.623076923076923,16.01923076923077,16.415384615384614,16.81153846153846,17.20769230769231,17.603846153846156,{"y":18,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.85,13.092307692307692,13.334615384615384,13.576923076923077,13.819230769230769,14.061538461538461,14.303846153846154,14.546153846153846,14.788461538461538,15.03076923076923,15.273076923076923,15.515384615384615,15.757692307692308,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.17,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.3,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.9,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.22,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.94,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.5,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.43,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.61,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.79,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.92,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.85,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >